MOTS-c Side Effects: Where the Preparation Is the Risk

Safety information in medicine comes from structured collection: adverse events recorded against a defined exposure, in a defined population, with a comparison group, over a defined window. That machinery produces a list that can be argued with, because every entry has a denominator behind it.

None of that exists here, and a registry search is the reason many pages think it does. NCT07505745 is listed as a Phase 2 study of MOTS-c for improving insulin sensitivity in adults with prediabetes and overweight or obesity, enrolment 120, status recruiting. Its lead sponsor, Hudson Biotech, holds eight such records posted between February and April 2026, covering BPC-157, Melanotan II, GHK-Cu, retatrutide, tesamorelin, tirzepatide, TB-500 and this compound, every one recruiting at a single site. NCT07487363, the TB-500 record, describes itself in its own brief summary as a fictional example of a ClinicalTrials.gov-style record. The remaining hits on that search are false matches on text.

So the denominator is not merely unpublished, it is absent. A count of hits is not a count of evidence, and an identifier that resolves is not a study that collected anything.

The compound holds no marketing authorisation from any regulator and is sold as a research chemical. There is therefore no approved product label, no summary of product characteristics, and no post-marketing surveillance stream, because there is no marketed product to surveil.

What circulates instead is self-report, uncontrolled and unattributed to a known preparation. That is not nothing, but it is not a safety profile, and treating it as one imports a confidence the underlying material does not carry.

Set the compound aside for a moment. A vial arrives as a dry powder, gets water added by hand, and is drawn from with a marked barrel. Each of those steps introduces a variable, and most of them are invisible at the point of use.

Every row in the last column says no. That is the reason the preparation deserves more attention than the compound in a discussion about risk: nothing about a filled syringe tells you which of these went wrong.

Two of those rows can be turned into numbers immediately.

The fill volume first. Concentration is labelled mass divided by added volume, so a 10 mg vial with an intended 2 mL gives 5 mg per mL, and a 0.1 mL draw holds 500 mcg. Add 1.6 mL by mistake and the concentration is 10 divided by 1.6, which is 6.25 mg per mL, so the same 0.1 mL now holds 625 mcg. The syringe reads 10 units in both cases. Nothing looks different. The quantity removed is a quarter larger.

The barrel next. A U-100 syringe fills 1 mL at 100 units, so one unit is 0.01 mL. A U-40 fills 1 mL at 40 units, so one unit is 0.025 mL. Reading a figure written for a U-100 off a U-40 barrel multiplies the volume by 2.5 before the contents are considered. Combine that with the fill volume error above and the two together are a factor of more than three, all of it invisible.

These are the errors arithmetic can catch, and it catches them only if the inputs were written down. An unrecorded fill volume is unrecoverable, which is why the record matters more than the calculator.

The efficacy literature is work in mice and in cultured cells, examining glucose handling and insulin sensitivity. Animal studies of this kind do observe the animals, and observations in mice under a controlled protocol are real data about mice.

They are a poor guide to what would be noticed in a person, for reasons that are structural rather than a matter of study quality. Species differ in clearance and in how they respond to a given route. Effects that depend on subjective report, which is a large share of what people mean by side effects, cannot be collected from an animal at all. And the exposure amounts are stated per kilogram of mouse body weight, in a model chosen to isolate a metabolic variable rather than to resemble ordinary human physiology.

Three categories sit entirely outside the arithmetic, and they are the ones worth naming plainly.

Contamination is the first. Sterility is a property of technique and of the diluent, not of a concentration. No division protects a preparation drawn with a contaminated needle, and the calculation will report a clean 500 mcg regardless.

Identity is the second. Nothing in a vial confirms that the powder is what the label says, or that it is only that. An assay answers this question. Arithmetic cannot, because it takes the label as an input and trusts it completely.

Degradation is the third. Peptide in solution is chemically less stable than sealed lyophilised powder, and the loss is not linear or visible. A concentration figure calculated on the day of reconstitution describes a vial that no longer exists three weeks later, and there is no correction factor to apply because nobody measured the decline.

A certificate of analysis is the one artefact that speaks to the identity row of the table above, and it is worth reading with the same care as a label.

The certificate describes a batch, not the individual vial in a buyer's hand, so the first check is whether the batch identifier on the paperwork matches the one on the vial. If it does not, the document is evidence about something else. The second check is what was actually tested. A purity figure produced by one analytical method is a statement about that method's view of the sample, and identity confirmation is a separate test from purity. A certificate that reports one and is silent on the other has answered half the question.

The third check is who performed it. Testing commissioned and published by the seller has an obvious interest attached, which does not make it false and does mean an independent assay carries more weight. None of this is arithmetic, and all of it sits upstream of the arithmetic, since every mass figure on this page begins with a labelled number that these documents are the only check on.